Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $61,384.40 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary Szela sold 15,944 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $3.85, for a total transaction of $61,384.40. Following the completion of the sale, the chief executive officer owned 752,987 shares in the company, valued at $2,898,999.95. This represents a 2.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

TriSalus Life Sciences Price Performance

Shares of TLSI opened at $3.93 on Monday. TriSalus Life Sciences, Inc. has a 1-year low of $3.42 and a 1-year high of $7.95. The stock has a market cap of $240.95 million, a price-to-earnings ratio of -2.15 and a beta of 0.42. The firm has a 50 day simple moving average of $4.91 and a 200-day simple moving average of $5.29.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The company had revenue of $13.21 million during the quarter, compared to analysts’ expectations of $13.20 million. On average, equities analysts expect that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current fiscal year.

Trending Headlines about TriSalus Life Sciences

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: TriSalus reported a slight quarterly earnings beat on March 5 (EPS -$0.12 vs. consensus -$0.13) with revenue roughly in line with expectations — this gives a fundamental rationale for buying interest. MarketBeat TLSI Summary
• Neutral Sentiment: Trading volume was elevated (≈396k shares vs. ~181k average), suggesting the market is actively re-pricing the name; price remains below the 50-day ($4.95) and 200-day ($5.30) moving averages, a neutral-to-cautious technical backdrop.
• Negative Sentiment: CEO Mary T. Szela sold 15,944 shares on March 17 at an average $3.85 (≈$61.4k) and previously sold 4,358 shares on March 11 at $4.13; these transactions reduced her ownership by ~2.07% and ~0.56% respectively — a notable insider reduction. CEO Form 4
• Negative Sentiment: Other officers also reported multiple small sales this week: Richard Marshak (several sales on Mar 11–16). These are modest in dollar terms but collectively add to negative insider-sentiment signals. Marshak Form 4
• Negative Sentiment: Insider sales by Bryan F. Cox (multiple small sales Mar 11–16) and Jodi Devlin (multiple small sales Mar 11–16) were also disclosed, further contributing to the selling narrative. Cox Form 4 Devlin Form 4

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. purchased a new position in TriSalus Life Sciences during the first quarter worth about $187,000. Geode Capital Management LLC grew its holdings in TriSalus Life Sciences by 107.4% in the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock valued at $2,480,000 after buying an additional 235,627 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at about $29,000. JPMorgan Chase & Co. increased its stake in shares of TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after acquiring an additional 7,519 shares during the last quarter. Finally, Connective Capital Management LLC lifted its holdings in shares of TriSalus Life Sciences by 12.8% during the 2nd quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock worth $179,000 after acquiring an additional 3,717 shares during the period. 2.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TLSI. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th. Canaccord Genuity Group decreased their price target on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Zacks Research raised shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, TriSalus Life Sciences presently has an average rating of “Hold” and an average price target of $7.00.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.